Hepatitis C Testing Market By Technique (Immunoassay, PCR, Other techniques), By Test (Antibody test, Genotype tests, Viral load test), By End User (Hospital and diagnostic laboratory, Blood banks, Other end users): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global hepatitis C testing market was valued at $1,329.0 million in 2021, and is projected to reach $2,248.2 million by 2031, registering a CAGR of 5.3% from 2022 to 2031. Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. The hepatitis C virus (HCV) spreads through contaminated blood. The hepatitis C can be diagnosed with antibody test, genotype test, and viral load test.
The increasing rate of hepatitis C and rise in awareness about hepatitis C drives the growth of market. For instance, according to a report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have the chronic hepatitis C infection. Thus, increase in prevalence of hepatitis C globally boosts the growth of the market.
In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis C virus transmission. For instance, as per the report of World Health Organization (WHO) published on May 2022, about 118.54 million blood donations are made worldwide. 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis C, and syphilis should be mandatory.
Moreover, increase in R&D activities for development of advanced hepatitis C testing such as immunoassay & polymerase chain reaction (PCR), rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in December 2020, Transasia Bio-Medicals, a leading Indian diagnostic company, announced the launch of India’s first, high sensitivity testing kit for hepatitis C virus. Based on the latest method, the ErbaLisa HCV Gen 4 Ag+Ab kit, is India’s first and only indigenously developed 4th gen ELISA kit and has been evaluated by the National Institute of Biologicals (NIB). Furthermore, advancements in hepatitis C diagnosis further contribute in market growth. However, the high cost of hepatitis C testing may hinder the growth of market.
The hepatitis C testing market is segmented on the basis of technique, test, end user, and region. By technique, market is fragmented into immunoassay, polymerase chain reaction (PCR), and others. The polymerase chain reaction (PCR) segment is further classified into real time PCR, and other PCR.
Depending on test, the market is classified into antibody test, genotype tests, and viral load test. On the basis of end user, the market is categorized into hospital & diagnostic laboratory, blood banks, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Abbott Laboratories, BIO-RAD laboratories Inc, Cosara Diagnostics Pvt Ltd, Illumina Inc, Meril Life Sciences Pvt. Ltd., Molbio Diagnostics Pvt. Ltd., PerkinElmer, Qiagen N.V., Thermo Fisher Scientific Inc, and Trivitron Healthcare.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis c testing market analysis from 2021 to 2031 to identify the prevailing hepatitis c testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hepatitis c testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hepatitis c testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technique
Immunoassay
PCR
Type
Real time PCR
Other PCR
Other techniques
By Test
Antibody test
Genotype tests
Viral load test
By End User
Hospital and diagnostic laboratory
Blood banks
Other end users
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Europe
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Abbott Laboratories
BIO-RAD laboratories Inc
Cosara Diagnostics Pvt Ltd
Illumina Inc
Meril Life Sciences Pvt. Ltd.
Molbio Diagnostics Pvt. Ltd.
PerkinElmer
Qiagen N.V.
Thermo Fisher Scientific Inc
Trivitron Healthcare
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: HEPATITIS C TESTING MARKET, BY TECHNIQUE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Immunoassay
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 PCR
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.3.4 PCR Hepatitis C Testing Market by Type
- 4.3.4.1 Real time PCR Market size and forecast, by region
- 4.3.4.2 Other PCR Market size and forecast, by region
- 4.4 Other techniques
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- CHAPTER 5: HEPATITIS C TESTING MARKET, BY TEST
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Antibody test
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Genotype tests
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Viral load test
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: HEPATITIS C TESTING MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospital and diagnostic laboratory
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Blood banks
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Other end users
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: HEPATITIS C TESTING MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Technique
- 7.2.2.1 North America PCR Hepatitis C Testing Market by Type
- 7.2.3 North America Market size and forecast, by Test
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Technique
- 7.2.5.1.2 Market size and forecast, by Test
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Technique
- 7.2.5.2.2 Market size and forecast, by Test
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Technique
- 7.2.5.3.2 Market size and forecast, by Test
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Technique
- 7.3.2.1 Europe PCR Hepatitis C Testing Market by Type
- 7.3.3 Europe Market size and forecast, by Test
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Technique
- 7.3.5.1.2 Market size and forecast, by Test
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Technique
- 7.3.5.2.2 Market size and forecast, by Test
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Technique
- 7.3.5.3.2 Market size and forecast, by Test
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Technique
- 7.3.5.4.2 Market size and forecast, by Test
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Technique
- 7.3.5.5.2 Market size and forecast, by Test
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Technique
- 7.3.5.6.2 Market size and forecast, by Test
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Technique
- 7.4.2.1 Asia-Pacific PCR Hepatitis C Testing Market by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Test
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Technique
- 7.4.5.1.2 Market size and forecast, by Test
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Technique
- 7.4.5.2.2 Market size and forecast, by Test
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Technique
- 7.4.5.3.2 Market size and forecast, by Test
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Technique
- 7.4.5.4.2 Market size and forecast, by Test
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Technique
- 7.4.5.5.2 Market size and forecast, by Test
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Europe
- 7.4.5.6.1 Market size and forecast, by Technique
- 7.4.5.6.2 Market size and forecast, by Test
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Technique
- 7.5.2.1 LAMEA PCR Hepatitis C Testing Market by Type
- 7.5.3 LAMEA Market size and forecast, by Test
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Technique
- 7.5.5.1.2 Market size and forecast, by Test
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Technique
- 7.5.5.2.2 Market size and forecast, by Test
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Technique
- 7.5.5.3.2 Market size and forecast, by Test
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Technique
- 7.5.5.4.2 Market size and forecast, by Test
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 BIO-RAD laboratories Inc
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Cosara Diagnostics Pvt Ltd
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Illumina Inc
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Meril Life Sciences Pvt. Ltd.
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Molbio Diagnostics Pvt. Ltd.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 PerkinElmer
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Qiagen N.V.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Thermo Fisher Scientific Inc
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Trivitron Healthcare
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 2. HEPATITIS C TESTING MARKET, FOR IMMUNOASSAY, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. HEPATITIS C TESTING MARKET FOR IMMUNOASSAY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. HEPATITIS C TESTING MARKET, FOR PCR, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. HEPATITIS C TESTING MARKET FOR PCR, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GLOBAL PCR HEPATITIS C TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 7. HEPATITIS C TESTING MARKET, FOR REAL TIME PCR, BY REGION, 2021-2031 ($MILLION)
- TABLE 8. HEPATITIS C TESTING MARKET, FOR OTHER PCR, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. HEPATITIS C TESTING MARKET, FOR OTHER TECHNIQUES, BY REGION, 2021-2031 ($MILLION)
- TABLE 10. HEPATITIS C TESTING MARKET FOR OTHER TECHNIQUES, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 11. GLOBAL HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 12. HEPATITIS C TESTING MARKET, FOR ANTIBODY TEST, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. HEPATITIS C TESTING MARKET FOR ANTIBODY TEST, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. HEPATITIS C TESTING MARKET, FOR GENOTYPE TESTS, BY REGION, 2021-2031 ($MILLION)
- TABLE 15. HEPATITIS C TESTING MARKET FOR GENOTYPE TESTS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 16. HEPATITIS C TESTING MARKET, FOR VIRAL LOAD TEST, BY REGION, 2021-2031 ($MILLION)
- TABLE 17. HEPATITIS C TESTING MARKET FOR VIRAL LOAD TEST, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 18. GLOBAL HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 19. HEPATITIS C TESTING MARKET, FOR HOSPITAL AND DIAGNOSTIC LABORATORY, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. HEPATITIS C TESTING MARKET FOR HOSPITAL AND DIAGNOSTIC LABORATORY, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. HEPATITIS C TESTING MARKET, FOR BLOOD BANKS, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. HEPATITIS C TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. HEPATITIS C TESTING MARKET, FOR OTHER END USERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. HEPATITIS C TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. HEPATITIS C TESTING MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. NORTH AMERICA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 27. NORTH AMERICA PCR HEPATITIS C TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 28. NORTH AMERICA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 29. NORTH AMERICA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 31. U.S. HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 32. U.S. HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 33. U.S. HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 34. CANADA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 35. CANADA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 36. CANADA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 37. MEXICO HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 38. MEXICO HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 39. MEXICO HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 40. EUROPE HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 41. EUROPE PCR HEPATITIS C TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 42. EUROPE HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 43. EUROPE HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 44. EUROPE HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 45. GERMANY HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 46. GERMANY HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 47. GERMANY HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 48. FRANCE HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 49. FRANCE HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 50. FRANCE HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 51. UK HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 52. UK HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 53. UK HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 54. ITALY HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 55. ITALY HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 56. ITALY HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 57. SPAIN HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 58. SPAIN HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 59. SPAIN HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 60. REST OF EUROPE HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 61. REST OF EUROPE HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 62. REST OF EUROPE HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 63. ASIA-PACIFIC HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 64. ASIA-PACIFIC PCR HEPATITIS C TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 65. ASIA-PACIFIC HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 68. JAPAN HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 69. JAPAN HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 70. JAPAN HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 71. CHINA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 72. CHINA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 73. CHINA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 74. AUSTRALIA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 75. AUSTRALIA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 77. INDIA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 78. INDIA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 79. INDIA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 80. SOUTH KOREA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 81. SOUTH KOREA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 83. REST OF EUROPE HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 84. REST OF EUROPE HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 85. REST OF EUROPE HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 86. LAMEA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 87. LAMEA PCR HEPATITIS C TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 88. LAMEA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 89. LAMEA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 90. LAMEA HEPATITIS C TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 91. BRAZIL HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 94. SAUDI ARABIA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 97. SOUTH AFRICA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 100. REST OF LAMEA HEPATITIS C TESTING MARKET, BY TECHNIQUE, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA HEPATITIS C TESTING MARKET, BY TEST, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA HEPATITIS C TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 103.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 104.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 105.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 106.ABBOTT LABORATORIES: NET SALES,
- TABLE 107.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 108.BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
- TABLE 109.BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
- TABLE 110.BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
- TABLE 111.BIO-RAD LABORATORIES INC: NET SALES,
- TABLE 112.BIO-RAD LABORATORIES INC: KEY STRATERGIES
- TABLE 113.COSARA DIAGNOSTICS PVT LTD: COMPANY SNAPSHOT
- TABLE 114.COSARA DIAGNOSTICS PVT LTD: OPERATING SEGMENTS
- TABLE 115.COSARA DIAGNOSTICS PVT LTD: PRODUCT PORTFOLIO
- TABLE 116.COSARA DIAGNOSTICS PVT LTD: NET SALES,
- TABLE 117.COSARA DIAGNOSTICS PVT LTD: KEY STRATERGIES
- TABLE 118.ILLUMINA INC: COMPANY SNAPSHOT
- TABLE 119.ILLUMINA INC: OPERATING SEGMENTS
- TABLE 120.ILLUMINA INC: PRODUCT PORTFOLIO
- TABLE 121.ILLUMINA INC: NET SALES,
- TABLE 122.ILLUMINA INC: KEY STRATERGIES
- TABLE 123.MERIL LIFE SCIENCES PVT. LTD.: COMPANY SNAPSHOT
- TABLE 124.MERIL LIFE SCIENCES PVT. LTD.: OPERATING SEGMENTS
- TABLE 125.MERIL LIFE SCIENCES PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 126.MERIL LIFE SCIENCES PVT. LTD.: NET SALES,
- TABLE 127.MERIL LIFE SCIENCES PVT. LTD.: KEY STRATERGIES
- TABLE 128.MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY SNAPSHOT
- TABLE 129.MOLBIO DIAGNOSTICS PVT. LTD.: OPERATING SEGMENTS
- TABLE 130.MOLBIO DIAGNOSTICS PVT. LTD.: PRODUCT PORTFOLIO
- TABLE 131.MOLBIO DIAGNOSTICS PVT. LTD.: NET SALES,
- TABLE 132.MOLBIO DIAGNOSTICS PVT. LTD.: KEY STRATERGIES
- TABLE 133.PERKINELMER: COMPANY SNAPSHOT
- TABLE 134.PERKINELMER: OPERATING SEGMENTS
- TABLE 135.PERKINELMER: PRODUCT PORTFOLIO
- TABLE 136.PERKINELMER: NET SALES,
- TABLE 137.PERKINELMER: KEY STRATERGIES
- TABLE 138.QIAGEN N.V.: COMPANY SNAPSHOT
- TABLE 139.QIAGEN N.V.: OPERATING SEGMENTS
- TABLE 140.QIAGEN N.V.: PRODUCT PORTFOLIO
- TABLE 141.QIAGEN N.V.: NET SALES,
- TABLE 142.QIAGEN N.V.: KEY STRATERGIES
- TABLE 143.THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
- TABLE 144.THERMO FISHER SCIENTIFIC INC: OPERATING SEGMENTS
- TABLE 145.THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
- TABLE 146.THERMO FISHER SCIENTIFIC INC: NET SALES,
- TABLE 147.THERMO FISHER SCIENTIFIC INC: KEY STRATERGIES
- TABLE 148.TRIVITRON HEALTHCARE: COMPANY SNAPSHOT
- TABLE 149.TRIVITRON HEALTHCARE: OPERATING SEGMENTS
- TABLE 150.TRIVITRON HEALTHCARE: PRODUCT PORTFOLIO
- TABLE 151.TRIVITRON HEALTHCARE: NET SALES,
- TABLE 152.TRIVITRON HEALTHCARE: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.HEPATITIS C TESTING MARKET SEGMENTATION
- FIGURE 2.HEPATITIS C TESTING MARKET,2021-2031
- FIGURE 3.HEPATITIS C TESTING MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.HEPATITIS C TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.HEPATITIS C TESTING MARKET,BY TECHNIQUE,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF IMMUNOASSAY HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PCR HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHER TECHNIQUES HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 16.HEPATITIS C TESTING MARKET,BY TEST,2021(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ANTIBODY TEST HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF GENOTYPE TESTS HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF VIRAL LOAD TEST HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 20.HEPATITIS C TESTING MARKET,BY END USER,2021(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL AND DIAGNOSTIC LABORATORY HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF BLOOD BANKS HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHER END USERS HEPATITIS C TESTING MARKET,2021-2031(%)
- FIGURE 24.HEPATITIS C TESTING MARKET BY REGION,2021
- FIGURE 25.U.S. HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 26.CANADA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 27.MEXICO HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 28.GERMANY HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 29.FRANCE HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 30.UK HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 31.ITALY HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 32.SPAIN HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 33.REST OF EUROPE HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 34.JAPAN HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 35.CHINA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 36.AUSTRALIA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 37.INDIA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 38.SOUTH KOREA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 39.REST OF EUROPE HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 40.BRAZIL HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 41.SAUDI ARABIA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH AFRICA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF LAMEA HEPATITIS C TESTING MARKET,2021-2031($MILLION)
- FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 48.COMPETITIVE DASHBOARD
- FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 50.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 51.BIO-RAD LABORATORIES INC.: NET SALES ,($MILLION)
- FIGURE 52.COSARA DIAGNOSTICS PVT LTD.: NET SALES ,($MILLION)
- FIGURE 53.ILLUMINA INC.: NET SALES ,($MILLION)
- FIGURE 54.MERIL LIFE SCIENCES PVT. LTD..: NET SALES ,($MILLION)
- FIGURE 55.MOLBIO DIAGNOSTICS PVT. LTD..: NET SALES ,($MILLION)
- FIGURE 56.PERKINELMER.: NET SALES ,($MILLION)
- FIGURE 57.QIAGEN N.V..: NET SALES ,($MILLION)
- FIGURE 58.THERMO FISHER SCIENTIFIC INC.: NET SALES ,($MILLION)
- FIGURE 59.TRIVITRON HEALTHCARE.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook